


Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 068528.0103	Serial No. 10/086,913
	Applicant: Higuchim, et al.	
	Filing Date March 1, 2002	Group 1652 1653
	Examiner: Maryann Monshipouri	



U.S. PATENT DOCUMENTS

*Exam. Initial.	No.	Document No.	Date	Name	Class	Subclass	Filing Date if Approximate.

FOREIGN PATENT DOCUMENTS

Exam Initial	No.	Document No.	Date	Country	Class	Subclass	Translation Yes No

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
M.M.		"A Side effect of neuraminidase inhibitor in a patient with liver cirrhosis" by Kaji, et al. <u>J. Infect. Chemother</u> , (2005)(11:41-43)
M.M.		"Structural Insights into the catalytic mechanism of Trypanosoma cruzi trans-sialidase" by Amaya, et al., <u>Structure</u> , Vol. 12, pp. 775-784, May 2004
M.M.		"Trypanosoma cruzi trans-sialidase as a new therapeutic tool in the treatment of chronic inflammatory diseases: possible action against mycoplasma and chlamydia" by Higuchi, <u>Medical Hypotheses</u> (2004)(63, 616-623).

NY02:531905.1	Examiner <i>M. Monshipouri</i>	Date Considered <i>2/21/06</i>
---------------	--------------------------------	--------------------------------

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. 068528.0103	Serial No. 10/086,913
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Higuchim, et al.	
	Filing Date March 1, 2002	Group 1652 1653
	Examiner: Maryann Monshipouri	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
M.M.		"Coinfection with mycoplasma pneumoniae and chlamydia pneumoniae in ruptured plaques associated with acute myocardia infarction" by Higuchi, et al., Arq. Bras Cardiol, Vol. 81, No. 1, 12-22, 2003.
M.M.		"Pathophysiology of the heart in chagas' disease: current status and new developments" by Higuchi, et al., 2003 European Society of Cardiology, pp. 96-107
M.M.		"Trypanosoma cruzi trans-sialidase operates through a covalent sialyl-enzyme intermediate: Tryosine is the catalytic nucleophile" by Watts, et al., J. Am. Chem. Soc. 2003, 125, 7532-7533.
M.M.		A possible role for complement in the pathogenesis of chronic chagasic cardiomyopathy" by Aiello, et al., Journal of Pathology, 2002, 197; 224-229
M.M.		The Crystal Structure and Mode of Action of Trans-sialidase, a key enzyme in trypanosoma cruzi pathogenesis by Buschiazzi, et al., Molecular Cell, Vol. 10, 757-758, Oct. 2002
M.M.		Intracellular DNA replication and long term survival of pathogenic mycoplasmas" by Dallo, et al., Microbial Pathogenesis, 2000, 29: 301-309
M.M.		Systematic mapping of hearts from chronic chagasic patients: the association between the occurrence of histopathological lesions and Trypanosoma cruzi antigens" by Palomino, et al., Annals of Tropical Medicine and Parasitology, Vol. 94, No. 6, 571-579 (2000).
M.M.		Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza by Treanor, et al., JAMA, Feb. 23, 2000, Vol. 283
M.M.		Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the treatment of Influenza A and B Virus Infections by Monto, et al., Journal of Infectious Diseases, 1999: 180; 254-61.
M.M.		Association of an increase in CD8+ T cells with the presence of trypanosoma cruzi antigens in chronic human chagasic mycoarditis by Higuchi, et al., Am. J.Trop. Med. Hyg., 56(5), 1997, pp. 485-489

NY02:531905.1	
Examiner <i>Al. Roashi</i>	Date Considered <i>2/21/06</i>

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 068528.0103	Serial No. 10/086,913
	Applicant: Higuchim, et al.	
	Filing Date March 1, 2002	Group 1652
	Examiner: Maryann Monshipouri	

[illegible]


NY02:531905.1

L. Marshy

2/21/06

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 068528.0103	Serial No. 10/086,913
	Applicant: Higuchim, et al.	
	Filing Date March 1, 2002	Group 1652 1653
	Examiner: Maryann Monshipouri	



U.S. PATENT DOCUMENTS

*Exam. Initial.	No.	Document No.	Date	Name	Class	Subclass	Filing Date if Approximate.


FOREIGN PATENT DOCUMENTS

Exam Initial	No.	Document No.	Date	Country	Class	Subclass	Translation Yes No

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
-	71	"A Side effect of neuraminidase inhibitor in a patient with liver cirrhosis" by Kaji, et al. <u>J. Infect. Chemother.</u> (2005)(11:41-43)
	72	"Structural Insights into the catalytic mechanism of Trypanosoma cruzi trans-sialidase" by Amaya, et al., <u>Structure</u> , Vol. 12, pp. 775-784, May 2004
	73	"Trypanosoma cruzi trans-sialidase as a new therapeutic tool in the treatment of chronic inflammatory diseases: possible action against mycoplasma and chlamydia" by Higuchi, <u>Medical Hypotheses</u> (2004)(63, 616-623).

533284	Examiner <i>M. Monshipouri</i>	Date Considered <i>2/24/06</i>
--------	--------------------------------	--------------------------------

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. 068528.0103	Serial No. 10/086,913
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	Applicant: Higuchim, et al.	
	Filing Date March 1, 2002	Group 1652 1653
	Examiner: Maryann Monshipouri	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	74	"Coinfection with mycoplasma pneumoniae and chlamydia pneumoniae in ruptured plaques associated with acute myocardia infarction" by Higuchi, et al., Arq. Bras Cardiol, Vol. 81, No. 1, 12-22, 2003.
	75	"Pathophysiology of the heart in Chagas' disease: current status and new developments" by Higuchi, et al., 2003 European Society of Cardiology, pp. 96-107
	76	"Trypanosoma cruzi trans-sialidase operates through a covalent sialyl-enzyme intermediate: Tryosine is the catalytic nucleophile" by Watts, et al., J. Am. Chem. Soc. 2003, 125, 7532-7533.
	77	A possible role for complement in the pathogenesis of chronic chagasic cardiomyopathy" by Aiello, et al., Journal of Pathology, 2002, 197; 224-229
	78	The Crystal Structure and Mode of Action of Trans-sialidase, a key enzyme in trypanosoma cruzi pathogenesis by Buschiazzo, et al., Molecular Cell, Vol. 10, 757-758, Oct. 2002
	79	Intracellular DNA replication and long term survival of pathogenic mycoplasmas" by Dallo, et al., Microbial Pathogenesis, 2000, 29: 301-309
	80	Systematic mapping of hearts from chronic chagasic patients: the association between the occurrence of histopathological lesions and Trypanosoma cruzi antigens" by Palomino, et al., Annals of Tropical Medicine and Parasitology, Vol. 94, No. 6, 571-579 (2000).
	81	Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza by Treanor, et al., JAMA, Feb. 23, 2000, Vol. 283
	82	Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the treatment of Influenza A and B Virus Infections by Monto, et al., Journal of Infectious Diseases, 1999: 180; 254-61.
	83	Association of an increase in CD8+ T cells with the presence of trypanosoma cruzi antigens in chronic human chagasic mycoarditis by Higuchi, et al., Am. J.Trop. Med. Hyg., 56(5), 1997, pp. 485-489

533284

Examiner

relationship

Date Considered

2/24/06

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office	Atty. Docket No. 068528.0103	Serial No. 10/086,913
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicant: Higuchim, et al.	
(2 or several sheets if necessary)	Filing Date March 1, 2002	Group 1652 3
	Examiner: Maryann Monshipouri	

Exam Initial	No.	OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)
	84	The role of active myocarditis in the development of heart failure in chronic chagas disease : a study based on endomyocardial biopsies by Highuci, et al., Clin. Cardiol. 10, 665-670 (1987)
	85	A Neuraminidase from Trypanosoma cruzi removes sialic acid from the surface of mammalian myocardial and endothelial cells by Libby, et al., J. Clin. Invest., Vol. 77, Jan. 1986, 127-135
	86	Adsorption of Mycoplasma pneumonia to neuraminic acid receptors of various cells and possible role in virulence by Sobeslavsky, et al. Journal of Bacteriology, Sept. 1968, p. 695-705.

533284	Examiner <i>M. Monshipouri</i>	Date Considered 2/24/06
--------	--------------------------------	-------------------------

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.